



## **WARNING LETTER**

Date: April 16, 2020

TO:

<u>support@canabd.com</u> – Nova Botanix LTD DBA CanaBD 5 >>BDBscn 11.04 0T9c 0.0011.0LETETTER 1[[ /4T (A)-1 11.04 [(242 (c)-27205 Tc 0 0b)ni bo4 -063 (

Page2 of 4 pages

diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.

Some examples of the claims on your websites that establish the intended use of your products and misleadingly represent them as safe and/or effective for the treatment or prevention of COVID-19<sup>4</sup> include:

Χ

Χ

Page4 of 4 pages

sell, or otherwise promote or make available in the United States. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC's Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC's concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.

Sincerely,

Donald D. Ashley Director Office of Compliance Center for Drug Evaluation and Research Food and Drug Administration

Sincerely,

Richard A. Quaresima Acting Associate Director Division of Advertising Practices Federal Trade Commission